Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Change in Account Payables (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Change in Account Payables data on record, last reported at -$186000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 2557.14% year-over-year to -$186000.0; the TTM value through Dec 2025 reached $1.1 million, up 663.18%, while the annual FY2025 figure was $1.1 million, 663.18% up from the prior year.
  • Change in Account Payables reached -$186000.0 in Q4 2025 per PLSE's latest filing, down from $274000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $712000.0 in Q1 2025 and bottomed at -$1.5 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $52500.0, with a median of $64000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: surged 6855.56% in 2021, then crashed 2557.14% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $185000.0 in 2021, then crashed by 321.08% to -$409000.0 in 2022, then skyrocketed by 206.85% to $437000.0 in 2023, then plummeted by 101.6% to -$7000.0 in 2024, then plummeted by 2557.14% to -$186000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$186000.0 in Q4 2025, $274000.0 in Q3 2025, and $332000.0 in Q2 2025.